Raju Kucherlapati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raju Kucherlapati has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Melanie Haas Kucherlapati
Department of Genetics, Harvard Medical School, Boston, MA, USA
7 shared publications Adam T. Boutin
6 shared publications- Ayumu Taguchi
Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
6 shared publications Dean E. Brenner
6 shared publications- Paul D. Lampe
Fred Hutchinson Cancer Center
6 shared publications - Qingxiang Yan
F. Hoffmann‐La Roche Ltd. Mississauga Ontario Canada
6 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 11 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (6) , eabm2382
A functional genomic approach to actionable gene fusions for precision oncology
Fusion genes represent a class of attractive therapeutic targets. Thousands of fusion genes have been identified in patients with cancer, but the functional consequences and therapeutic implications of most of these remain largely unknown. Here, we develop a functional genomic approach that consists of efficient fusion reconstruction and sensitive cell viability and drug response assays. Applying this approach, we characterize ~100 fusion genes detected in patient samples of The Cancer Genome Atlas, revealing a notable fraction of low-frequency fusions with activating effects on tumor growth. Focusing on those in the RTK-RAS pathway, we identify a number of activating fusions that can markedly affect sensitivity to relevant drugs. Last, we propose an integrated, level-of-evidence classification system to prioritize gene fusions systematically. Our study reiterates the urgent clinical need to incorporate similar functional genomic approaches to characterize gene fusions, thereby maximizing the utility of gene fusions for precision oncology.
- 11 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (6) , eabm2382
Open AccessA functional genomic approach to actionable gene fusions for precision oncology
Fusion genes represent a class of attractive therapeutic targets. Thousands of fusion genes have been identified in patients with cancer, but the functional consequences and therapeutic implications of most of these remain largely unknown. Here, we develop a functional genomic approach that consists of efficient fusion reconstruction and sensitive cell viability and drug response assays. Applying this approach, we characterize ~100 fusion genes detected in patient samples of The Cancer Genome Atlas, revealing a notable fraction of low-frequency fusions with activating effects on tumor growth. Focusing on those in the RTK-RAS pathway, we identify a number of activating fusions that can markedly affect sensitivity to relevant drugs. Last, we propose an integrated, level-of-evidence classification system to prioritize gene fusions systematically. Our study reiterates the urgent clinical need to incorporate similar functional genomic approaches to characterize gene fusions, thereby maximizing the utility of gene fusions for precision oncology.
- Open Access
- 9 February 2017
- Published by Springer Nature in Nature
- Vol. 542 (7640) , 166
Oliver Smithies (1925–2017)
- 9 February 2017
- Published by Springer Nature in Nature
- Vol. 542 (7640) , 166
Open AccessOliver Smithies (1925–2017)
- Open Access
- 1 November 2015
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 8 (11) , 1112-1119
MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
Blood-based biomarkers for early detection of colorectal cancer could complement current approaches to colorectal cancer screening. We previously identified the APC-binding protein MAPRE1 as a potential colorectal cancer biomarker. Here, we undertook a case–control validation study to determine the performance of MAPRE1 in detecting early colorectal cancer and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early colorectal cancer, 30 with advanced colorectal cancer, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and carcinoembryonic antigen (CEA) was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in colorectal cancer mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with colorectal cancer compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early colorectal cancer from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early colorectal cancer patient plasma samples and in plasma from colorectal cancer mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early colorectal cancer, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage colorectal cancer and adenomas together with other biomarkers. Cancer Prev Res; 8(11); 1112–9. ©2015 AACR.
- 1 November 2015
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 8 (11) , 1112-1119
Open AccessMAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
Blood-based biomarkers for early detection of colorectal cancer could complement current approaches to colorectal cancer screening. We previously identified the APC-binding protein MAPRE1 as a potential colorectal cancer biomarker. Here, we undertook a case–control validation study to determine the performance of MAPRE1 in detecting early colorectal cancer and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early colorectal cancer, 30 with advanced colorectal cancer, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and carcinoembryonic antigen (CEA) was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in colorectal cancer mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with colorectal cancer compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early colorectal cancer from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early colorectal cancer patient plasma samples and in plasma from colorectal cancer mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early colorectal cancer, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage colorectal cancer and adenomas together with other biomarkers. Cancer Prev Res; 8(11); 1112–9. ©2015 AACR.
- Open Access
- 22 February 2007
- Published by Springer Nature in Leukemia
- Vol. 21 (5) , 1108-1109
Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia
- 22 February 2007
- Published by Springer Nature in Leukemia
- Vol. 21 (5) , 1108-1109
Open AccessMutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia